ARK102

ARK102 is a novel trispecific T-cell engager (TCE) developed by Arum Therapeutics for the treatment of solid tumors. Engineered using a proprietary platform, ARK102 is a fragment-based molecule that lacks an Fc domain, a design choice intended to enhance tumor penetration and reduce Fc-mediated off-target toxicities. The drug simultaneously targets two well-validated tumor-associated antigens, HER2 (Human Epidermal Growth Factor Receptor 2) and TROP2 (Trophoblast Cell-Surface Antigen 2), while recruiting cytotoxic T cells through the CD3 receptor. This dual-targeting strategy is designed to increase binding avidity and overcome resistance mechanisms such as tumor heterogeneity and antigen loss. Preclinical data presented at the AACR 2026 meeting demonstrated that ARK102 induces potent, dose-dependent T-cell activation and tumor cell lysis in models expressing either or both targets, showing efficacy comparable to or exceeding that of established HER2- and TROP2-directed antibody-drug conjugates (ADCs).